Q1 Earnings Estimate for GH Research Issued By HC Wainwright

GH Research PLC (NASDAQ:GHRS) – Analysts at HC Wainwright issued their Q1 2027 EPS estimates for GH Research in a note issued to investors on Thursday, March 12th. HC Wainwright analyst P. Trucchio anticipates that the company will earn ($0.34) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for GH Research’s Q2 2027 earnings at ($0.39) EPS, Q3 2027 earnings at ($0.43) EPS and Q4 2027 earnings at ($0.39) EPS.

Other equities analysts have also recently issued research reports about the stock. Wolfe Research set a $39.00 price target on shares of GH Research in a research note on Tuesday, January 6th. Citizens Jmp raised their price objective on shares of GH Research from $39.00 to $42.00 and gave the company a “market outperform” rating in a research note on Friday, March 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a research note on Thursday, January 22nd. TD Cowen reiterated a “buy” rating on shares of GH Research in a report on Monday, January 5th. Finally, Guggenheim set a $34.00 price target on GH Research and gave the company a “buy” rating in a report on Tuesday, March 10th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.13.

GH Research Stock Up 1.7%

GH Research stock opened at $15.36 on Monday. GH Research has a twelve month low of $7.98 and a twelve month high of $19.51. The company has a market capitalization of $952.78 million, a P/E ratio of -19.20 and a beta of 1.00. The stock’s 50 day moving average is $15.74 and its 200 day moving average is $14.36.

GH Research (NASDAQ:GHRS) last released its earnings results on Thursday, March 5th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.06.

Hedge Funds Weigh In On GH Research

Several institutional investors have recently bought and sold shares of the business. Barclays PLC lifted its holdings in GH Research by 63.4% during the fourth quarter. Barclays PLC now owns 2,118 shares of the company’s stock worth $27,000 after buying an additional 822 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of GH Research in the 4th quarter worth $38,000. Osaic Holdings Inc. lifted its stake in shares of GH Research by 63.6% during the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after purchasing an additional 2,400 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in GH Research during the second quarter valued at about $79,000. Finally, Virtus Investment Advisers LLC purchased a new position in GH Research in the second quarter valued at about $89,000. 56.90% of the stock is owned by hedge funds and other institutional investors.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.